| Kent E Swogger, CRNA | |
|
207 S Main St, Berryville, AR 72616-3921 | |
| (870) 423-4949 | |
| (870) 423-4754 |
| Full Name | Kent E Swogger |
|---|---|
| Gender | Male |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | 207 S Main St, Berryville, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134177280 | NPI | - | NPPES |
| 59253 | Other | AR | BCBS |
| 912707007 | Medicaid | MO | |
| 113181001 | Medicaid | AR | |
| 430022115 | Other | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | C00517 (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kent E Swogger, CRNA Po Box 557, Berryville, AR 72616-0557 Ph: (870) 423-4949 | Kent E Swogger, CRNA 207 S Main St, Berryville, AR 72616-3921 Ph: (870) 423-4949 |
News Archive
Z-Medica Corporation, a medical device company developing innovative hemostatic agents, today announced that it has signed an exclusive distribution agreement with Nihon-Kohden, Japan's leading manufacturer, developer and distributor of medical electronic equipment . The agreement allows Nihon-Kohden the exclusive right to distribute Z-Medica's QuikClot line of hemostatic agents to hospital, military and law enforcement markets throughout Japan. The companies have been working together since early 2009 to obtain regulatory approval.
Callidus Software Inc., the leader in Sales Performance Management (SPM), today announced that Blue Cross Blue Shield of North Carolina (BCBSNC), has selected the Callidus Monaco Suite to manage sales performance and incentive compensation programs. Under the enterprise class SaaS agreement, signed in the third quarter of 2009, BCBSNC will use the Callidus Monaco Suite for its 4,000 brokers.
Investigators at Children's Hospital Los Angeles have found that a common therapeutic target for the treatment of inflammatory bowel disease (IBD) may actually protect against intestinal inflammation by inhibiting pathogenic T-cells. This discovery, reported in the October 2015 issue of Gastroenterology, could lead to new treatment options for the 65 percent of individuals with IBD who do not respond or become resistant to anti-TNF medications.
An accurate, non-invasive, and low-cost method of testing for COVID-19 using samples taken from the screens of mobile phones has been developed by a team led by UCL researchers at Diagnosis Biotech.
› Verified 7 days ago